Searchable abstracts of presentations at key conferences in endocrinology

ea0040oc2 | (1) | ESEBEC2016

mTOR pathway activation in papillary thyroid carcinomas: associations and correlations

Tavares Catarina , Coelho Maria , Melo Miguel , Rocha Adriana , Pestana Ana , Batista Rui , Salgado Catarina , Eloy Catarina , Rios Elisabete , Ferreira Luciana , Sobrinho-Simoes M , Soares Paula

Background: Mammalian target of rapamycin (mTOR) is a downstream effector of the PI3K/AKT pathway. It can be activated by diverse stimuli, such as growth factors, nutrients, energy, stress signals and signaling pathways such as PI3K, MAPK and AMPK, in order to control cell growth, proliferation and survival. The active form of mTOR (pmTOR) may form two distinct complexes: mTORC1 that activates S6K1 and 4EBP1 which are involved in mRNA translation; and mTORC2 that activates PKC...

ea0040p4 | (1) | ESEBEC2016

Expression of osteopontin isoforms is related with thyroid cancer growth and invasion

Ferreira Luciana Bueno , Tavares Catarina , Pestana Ana , Leite Catarina , Eloy Catarina , Rios Elisabete , Celestino Ricardo , Batista Rui , Sobrinho-Simoes Manuel , Gimba Etel , Soares Paula

Osteopontin (OPN) is a matricellular protein highly expressed in cancer cells, which is able to modulate tumorigenesis and metastasis in several malignancies, including follicular cell-derived thyroid cancers (TC). OPN is one of the gene products aberrantly expressed in TC, but the contribution of each OPN isoform (OPNi), named as OPNa, OPNb and OPNc, is currently unknown. This study aims to analyze the expression profile of OPNi in TC tissue samples, correlate its expression ...

ea0049ep1449 | Thyroid (non-cancer) | ECE2017

The usefulness of the study of sodium iodide symporter expression in thyroid primary tumors

Tavares Catarina , Coelho Maria Joao , Eloy Catarina , Melo Miguel , da Rocha Adriana Gaspar , Pestana Ana , Batista Rui , Ferreira Luciana Bueno , Rios Elisabete , Cavadas Bruno , Pereira Luisa , Selmi-Ruby Samia , Simoes Manuel Sobrinho , Soares Paula

Thyroid cancer therapy is based on surgery followed by radioiodine treatment of tumor remnants and metastases. The incorporation of radioiodine by cancer cells is mediated by sodium iodide symporter (NIS), normally present in thyroid follicular cellsÂ’ membrane. We studied the expression of NIS in a series of 229 thyroid primary tumors using real time PCR and immunohistochemistry, and searched for possible associations between NIS expression and clinicopathological feature...